Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 4
2017 6
2018 7
2019 8
2020 10
2021 8
2022 8
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Rituximab treatment in myasthenia gravis.
Vesperinas-Castro A, Cortés-Vicente E. Vesperinas-Castro A, et al. Among authors: cortes vicente e. Front Neurol. 2023 Oct 2;14:1275533. doi: 10.3389/fneur.2023.1275533. eCollection 2023. Front Neurol. 2023. PMID: 37849836 Free PMC article. Review.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome.
Cortés-Vicente E, Álvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, Casasnovas C, Gómez-Caravaca MT, Pardo J, Ramos-Fransi A, Pelayo-Negro AL, Gutiérrez-Gutiérrez G, Turon-Sans J, López de Munain A, Guerrero-Sola A, Jericó I, Martín MA, Mendoza MD, Morís G, Vélez-Gómez B, Garcia-Sobrino T, Pascual-Goñi E, Reyes-Leiva D, Illa I, Gallardo E. Cortés-Vicente E, et al. Ann Clin Transl Neurol. 2022 Feb;9(2):122-131. doi: 10.1002/acn3.51492. Epub 2022 Jan 26. Ann Clin Transl Neurol. 2022. PMID: 35080153 Free PMC article.
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy.
Martín-Aguilar L, Lleixà C, Pascual-Goñi E, Caballero-Ávila M, Martínez-Martínez L, Díaz-Manera J, Rojas-García R, Cortés-Vicente E, Turon-Sans J, de Luna N, Suárez-Calvet X, Gallardo E, Rajabally Y, Scotton S, Jacobs BC, Baars A, Cortese A, Vegezzi E, Höftberger R, Zimprich F, Roesler C, Nobile-Orazio E, Liberatore G, Hiew FL, Martínez-Piñeiro A, Carvajal A, Piñar-Morales R, Usón-Martín M, Albertí O, López-Pérez MÁ, Márquez F, Pardo-Fernández J, Muñoz-Delgado L, Cabrera-Serrano M, Ortiz N, Bartolomé M, Duman Ö, Bril V, Segura-Chávez D, Pitarokoili K, Steen C, Illa I, Querol L. Martín-Aguilar L, et al. Among authors: cortes vicente e. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 2;9(1):e1098. doi: 10.1212/NXI.0000000000001098. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34728497 Free PMC article.
Clinicopathological correlates in frontotemporal lobar degeneration: motor neuron disease spectrum.
Carbayo Á, Borrego-Écija S, Turon-Sans J, Cortés-Vicente E, Molina-Porcel L, Gascón-Bayarri J, Rubio MÁ, Povedano M, Gámez J, Sotoca J, Juntas-Morales R, Almendrote M, Marquié M, Sánchez-Valle R, Illán-Gala I, Dols-Icardo O, Rubio-Guerra S, Bernal S, Caballero-Ávila M, Vesperinas A, Gelpi E, Rojas-García R. Carbayo Á, et al. Among authors: cortes vicente e. Brain. 2024 Jan 16:awae011. doi: 10.1093/brain/awae011. Online ahead of print. Brain. 2024. PMID: 38227807
Diagnostic utility of cortactin antibodies in myasthenia gravis.
Illa I, Cortés-Vicente E, Martínez MÁ, Gallardo E. Illa I, et al. Among authors: cortes vicente e. Ann N Y Acad Sci. 2018 Jan;1412(1):90-94. doi: 10.1111/nyas.13502. Epub 2017 Oct 25. Ann N Y Acad Sci. 2018. PMID: 29068555 Review.
Antibodies against the flotillin-1/2 complex in patients with multiple sclerosis.
Lleixà C, Caballero-Ávila M, Pascual-Goñi E, Martín-Aguilar L, Vidal N, Tejada C, Valdés-Hevia E, Zárate E, Vesperinas A, Collet R, Franco-Leyva T, Martínez-Martínez L, Moga E, Cortés-Vicente E, Rojas-García R, Gómez-Anson B, Gil A, González-Mingot C, Brieva L, Martínez-Yélamos S, Querol L. Lleixà C, et al. Among authors: cortes vicente e. Brain Commun. 2023 Apr 4;5(2):fcad109. doi: 10.1093/braincomms/fcad109. eCollection 2023. Brain Commun. 2023. PMID: 37091585 Free PMC article.
56 results